BriaCell Awarded National Cancer Institute Grant to Advance Its Bria-Ots^™ Immunotherapy for Cancer

The grant award of non-dilutive fund for “An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors”, will be used for the development of Bria-OTS™, BriaCell’s novel personalized off-the-shelf immunotherapies for advanced metastatic breast cancer, prostate cancer, lung cancer, and melanoma.